



NORTHSIDE HOSPITAL CANCER INSTITUTE

IMMUNOTHERAPY PROGRAM



The Immunotherapy Program at Northside Hospital Cancer Institute is a Certified Treatment Center for Abecma® (idecabtagene vicleucel). Abecma® is the first-in-class BCMA directed chimeric antigen receptor (CAR) T-cell immunotherapy for patients with relapsed/refractory (R/R) multiple myeloma after four or more prior lines of therapy including, an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 monoclonal antibody.

CAR T-cell therapy uses the patient's own cells to attack target cells with a specific protein on their surface. In multiple myeloma, the overexpression of BCMA significantly promotes the myeloma cell growth and survival. Abecma® recognizes and binds to BCMA, a protein that is nearly universally expressed on the surface of normal and malignant plasma cells blocking multiple myeloma cell proliferation.



Relapse and Refractory Multiple Myeloma

Deep, Rapid and Durable Response:

- In the pivotal KarMMA trial, 72% of patients achieved a rapid deep and durable response. The median time to response was 30 days.

Safety Profile:

- Safety profile of Abecma® is well established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution.

Multiple Myeloma CAR T-Cell Therapy Clinical Trial Options

- A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of BB2121 in Subjects with High-Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)
 - This study is for **newly** diagnosed high-risk multiple myeloma. All patients will receive BB2121.
- An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (IDE-CEL) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma (KarMMa-7)
 - This study will evaluate the combination of CAR-T therapy with drugs which may potentiate its activity in patients with R/R multiple myeloma. Two cohorts of patients will be enrolled: those with 1-3 prior lines of therapy and those with ≥ 3 prior lines of therapy.
 - Two cohorts of patients will be enrolled: those with 1-3 prior lines of therapy and those with ≥ 3 prior lines of therapy.

Optimal timing for referral of R/R multiple myeloma patients is at disease progression following their second or later line of therapy. Newly diagnosed high-risk patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility.

Please call **404-255-1930** to initiate a referral or to speak to a physician.
bmtga.com/immunotherapy-program-at-northside or northside.com/immunotherapy



**NORTHSIDE
HOSPITAL**

CANCER INSTITUTE

BUILT TO BEAT CANCER